Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy Participants

Phase 1 Recruiting 49 enrolled Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

RandomizedSequentialQuadruple-blindOther

Summary

The present study in healthy participants will assess the safety, tolerability, immunogenicity, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses (SAD) of subcutaneously administered M5542.

Timeline

Start: 2024-09-12
Primary completion: 2026-11-16
Completion: 2027-03-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	M5542	Unknown	—	Subcutaneous

Indications

No indication recorded.